Palisade Bio (PALI) Liabilities and Shareholders Equity (2010 - 2026)

Palisade Bio (PALI) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $133.3 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1527.78% year-over-year to $133.3 million in Q1 2026; TTM through Mar 2026 was $281.3 million, a 581.49% increase from a year earlier, with the FY2025 full-year figure at $134.3 million, up 1134.78% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $133.3 million, down from $134.3 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PALI reached as high as $134.3 million in Q4 2025 and fell as low as $6.7 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $26.4 million across 5 years, with a median of $12.9 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity plunged 48.2% in 2025 and jumped 1527.78% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $15.8 million in 2022, then declined by 10.85% to $14.1 million in 2023, then dropped by 22.57% to $10.9 million in 2024, then soared by 1134.78% to $134.3 million in 2025, then declined by 0.77% to $133.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $133.3 million in Q1 2026, $134.3 million in Q4 2025, and $7.0 million in Q3 2025.